Close Menu

Amgen

The FDA has confirmed to DxS that its TheraScreen KRAS test is a Class III device. The company is in the process of submitting its premarket approval application to the agency.

Imperial College London and its spinout DNA Electronics have created a prototype for the so-called SNP Dr., which is being developed under a £1.2 million project that also includes Pfizer.

Top executives last week from Alexandria Real Estate Equities, BioMed Realty Trust, and HCP said life-sci shops are increasingly skittish about leasing new space for the long term, leading the REITs to reduce spending on construction and renovation projects this year.

Michael Kirschner, Vernon George, Norma Grace, Sherman McCorkle, Austin Beggs, Michael Donovan, Scott Levitan, Jinx Patel

Without specific guidance from the FDA regarding KRAS testing, drugmakers Bristol-Myers Squibb and Amgen are facing lower sales of their colorectal cancer drugs Erbitux and Vectibix, and may need to get creative in how they market their drugs to patients and doctors.

Navigenics’ lower-priced program to incorporate genetic risk data in patients’ annual medical checkup raises questions as to whether personal genomics firms should be broadly marketing their services to physicians.

Pages

A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.

A new analysis finds some cancers receive more nonprofit dollars than others.

An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.

In Science this week: comparative analysis of sex differences in mammal gene expression, and more.